<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01882920</url>
  </required_header>
  <id_info>
    <org_study_id>89/10</org_study_id>
    <nct_id>NCT01882920</nct_id>
  </id_info>
  <brief_title>Goal Directed Therapy (GDT) in Cytoreductive Surgery (CRS) and Hyperthermic Intra Peritoneal Chemotherapy (Hipec)</brief_title>
  <official_title>Cytoreductive Surgery With Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) - Goal Directed Therapy vs. Standard Fluid Therapy. Prospective Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regina Elena Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regina Elena Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess whether in cytoreductive surgery (CRS) and hyperthermic
      intraperitoneal chemotherapy (HIPEC) the use of a protocol of intravenous fluid therapy
      combined with goal directed fluid therapy (GDT) is associated with a significant change in
      morbidity, length of hospital stay and mortality compared to a standard fluid therapy.
      Patients undergoing CRS and hipec are randomly divided into two treatment groups. The GDT
      group receive fluid intravenous therapy according to a specific treatment protocol guided by
      monitored hemodynamic parameters assessed using the arterial pressure signal monitoring to
      assess stroke volume and cardiac output via an automated pulse contour analysis
      (Flotrac/VigileoÂ®); the control group receive the standard fluid therapy (crystalloid and
      colloid). Fluid therapy regimen is free in the control group and targeted in the GDT group.
      In both groups, the investigators evaluate the incidence of major abdominal and systemic
      complications, the total duration of hospital stay, mortality, the total amount of fluids
      administered, their breakdown (crystalloid/colloid) and the total number of colloid boluses
      administered.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rate of abdominal complications</measure>
    <time_frame>90 day postoperative complication</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>90 day overall survival</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>length of hospital stay</measure>
    <time_frame>4 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Primary Peritoneal Neoplasm</condition>
  <condition>Secondary Peritoneal Neoplasm</condition>
  <arm_group>
    <arm_group_label>Goal directed therapy intravenous restricitve fluid protocol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goal Directed Intravenous Restrictive Fluid Therapy</intervention_name>
    <description>Basal infusion of crystalloids (normal saline,Ringer's lactate,Ringer's solution) at 4 ml/kg/h and boluses of colloids (HES 130/0.4 ) for values of cardiac index (CI) &lt;2.5 l/min/m2, stroke volume index (SVI) &lt; 35 SVI ml/m2 and stroke volume variation (SVV)&gt; 15%. In the case of CI &lt;2.5 l/min/m2 and SVI &lt;35 ml/m2 with SVV &lt; 15%, an infusion with dopamine was initiated.</description>
    <arm_group_label>Goal directed therapy intravenous restricitve fluid protocol</arm_group_label>
    <other_name>Normal Saline</other_name>
    <other_name>Ringer's lactate</other_name>
    <other_name>Ringer's solution</other_name>
    <other_name>Hydroxyethyl starch 130/0,4 (HES 130,04)</other_name>
    <other_name>Automated pulse contour</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conventional Intravenous Fluid therapy</intervention_name>
    <description>Basal infusion of crystalloid (normal saline,Ringer's lactate,Ringer's solution)variable from 4 to 12 ml/kg/hour.</description>
    <arm_group_label>Control arm</arm_group_label>
    <other_name>Normal saline</other_name>
    <other_name>Ringer's lactate</other_name>
    <other_name>Ringer's solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients selected for Cytoreductive surgery and hyperthermic intraperitoneal
             chemotherapy

        Exclusion Criteria:

          -  Patients under the age of 18, patients with hemodynamically significant aortic
             regurgitation and heart rhythm disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ester Forastiere, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Regina Elena CI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regina Elena CI</name>
      <address>
        <city>Rome</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2013</study_first_submitted>
  <study_first_submitted_qc>June 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2013</study_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Regina Elena Cancer Institute</investigator_affiliation>
    <investigator_full_name>Ester Forastiere</investigator_full_name>
    <investigator_title>M.D., Chief of Critical Area Department</investigator_title>
  </responsible_party>
  <keyword>Cytoreductive surgery</keyword>
  <keyword>hyperthermic intraperitoneal chemotherapy</keyword>
  <keyword>Goal directed fluid therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Fever</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

